Protocol Ledger

NCT05972135 · Phase II · RECRUITING

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Interventional Phase II clinical trial protocol NCT05972135 sponsored by SCRI Development Innovations in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-23 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05972135
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05972135
Protocol FieldVerified Registry Value
NCT IdentifierNCT05972135
Consolidated Lead SponsorSCRI Development Innovations
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2023-10-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05972135
Hospital Research SiteLocationSite Profile
Colorado Blood Cancer InstituteDenver, COOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI